Imaging Biomarkers as Predictors for Breast Cancer Death
Files
(Published version)
Date
2019
Authors
Wu, W.Y.Y.
Tabar, L.
Tot, T.
Fann, C.Y.
Yen, A.M.F.
Chen, S.L.S.
Chiu, S.Y.H.
Ku, M.M.S.
Hsu, C.Y.
Beckmann, K.R.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Oncology, 2019; 2019(2087983)
Statement of Responsibility
Conference Name
Abstract
<h4>Background</h4>To differentiate the risk of breast cancer death in a longitudinal cohort using imaging biomarkers of tumor extent and biology, specifically, the mammographic appearance, basal phenotype, histologic tumor distribution, and conventional tumor attributes.<h4>Methods</h4>Using a prospective cohort study design, 498 invasive breast cancer patients diagnosed between 1996 and 1998 were used as the test cohort to assess the independent effects of the imaging biomarkers and other predictors on the risk of breast cancer death. External validation was performed with a cohort of 848 patients diagnosed between 2006 and 2010.<h4>Results</h4>Mammographic tumor appearance was an independent predictor of risk of breast cancer death (P=0.0003) when conventional tumor attributes and treatment modalities were controlled. The casting type calcifications and architectural distortion were associated with 3.13-fold and 3.19-fold risks of breast cancer death, respectively. The basal phenotype independently conferred a 2.68-fold risk compared with nonbasal phenotype. The observed deaths did not differ significantly from expected deaths in the validation cohort. The application of imaging biomarkers together with other predictors classified twelve categories of risk for breast cancer death.<h4>Conclusion</h4>Combining imaging biomarkers such as the mammographic appearance of the tumor with the histopathologic distribution and basal phenotype, accurately predicted long-term risk of breast cancer death. The information may be relevant for determining the need for molecular testing, planning treatment, and determining the most appropriate clinical surveillance schedule for breast cancer patients.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2019 Wendy Yi-Ying Wu et al. Tis is an open access article distributed under the Creative Commons AttributionLicense, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properlycited.